Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections
The plant will help make Lilly's experimental drug called retatrutide, which has shown the highest weight loss seen to date in a late-stage trial.
TL;DR
- Eli Lilly will invest over $3.5 billion to construct a new manufacturing plant in Pennsylvania's Lehigh Valley.
- The plant will focus on producing next-generation obesity drugs, including the experimental drug retatrutide.
- Construction is slated to begin this year, with the site becoming operational in 2031.
- This is the fourth new U.S. facility announced by Lilly as part of significant domestic investment plans.
- The company aims to increase production capacity for upcoming weight loss treatments to maintain dominance in the GLP-1 market.
- The Pennsylvania plant is expected to create 850 jobs, plus 2,000 construction jobs.
- Drugmakers are increasing U.S. production partly due to past threats of tariffs on imported pharmaceuticals.